

The Rx Consultant

Index to Volume XVI (2007 Issues)

January

Number 1 - Asthma Management: Focus on Long-Acting Inhaled Bronchodilators

Reviews stepwise treatment strategies for controlling asthma symptoms based on severity classification. Summarizes asthma trigger management and the use of short-acting beta₂-agonists and inhaled corticosteroids. A detailed discussion of the role of inhaled long-acting beta₂-agonists (LABAs), including risks and warnings, is provided.

Drugs included in this issue:

Long-Acting Inhaled Beta₂-Agonists

salmeterol xinafoate (*Serevent Diskus*[®])
 fluticasone propionate / salmeterol xinafoate (*Advair Diskus*[®])
 fluticasone propionate / salmeterol xinafoate (*Advair*[®] HFA)

formoterol fumarate (*Foradil Aerolizer*[®])
 budesonide / formoterol fumarate (*Symbicort*[®] HFA)

Short-Acting Inhaled Beta₂-Agonist

albuterol (*Ventolin*[®], *Proventil*[®])

Inhaled Corticosteroids

beclomethasone dipropionate (*QVAR*[®])
 budesonide (*Pulmicort Turbuhaler*[®])
 flunisolide (*Aerobid*[®])
 fluticasone (*Flovent*[®])
 triamcinolone acetonide (*Azmacort*[®])
 mometasone (*Asmanex*[®])

February

Number 2 - Breast Cancer

Presents an overview of breast cancer management focusing on the use of hormonal therapy. Reviews the stages and types of breast cancer and how these, and other factors including menopausal and hormone receptor status, influence treatment choices. Discusses the use of aromatase inhibitors as first line adjuvant hormonal therapy.

Drugs reviewed in this issue:

Selective Estrogen Receptor Modulators (SERMs)

tamoxifen citrate (*Soltamox*[®], others)
 raloxifene (*Evista*[®])
 toremifene (*Fareston*[®])

Estrogen Receptor Down Regulator (ERD)

fulvestrant (*Faslodex*[®])

Aromatase Inhibitors (AIs)

anastrozole (*Arimidex*[®])
 letrozole (*Femara*[®])
 exemestane (*Aromasin*[®])

March

Number 3 - Allergic Rhinitis

Outlines the classification system for allergic rhinitis (AR) and reviews current treatment recommendations. Explains the rationale behind allergy testing and the role of immunotherapy. Specific recommendations for the treatment of AR in special populations (children, pregnant women, elderly adults, and individuals with asthma) are also detailed.

Drugs included in this issue:

Nasal Corticosteroids
 beclomethasone dipropionate (*Beconase AQ*[®])
 budesonide HCl (*Rhinocort Aqua*[®])
 ciclesonide (*Omnaris*[®])
 flunisolide (*Nasarel*[®])
 fluticasone propionate (*Flonase*[®])
 mometasone furoate (*Nasonex*[®])
 triamcinolone acetonide (*Nasacort*[®] HFA, *Nasacort AQ*[®])

1st generation Antihistamines

chlorpheniramine maleate
 clemastine fumarate
 diphenhydramine HCl
 brompheniramine

2nd generation Antihistamines

cetirizine (*Zyrtec*[®])
 fexofenadine (*Allegra*[®])
 loratadine (*Claritin*[®], *Alavert*[®])
 desloratadine (*Clarinex*[®])

Decongestants

pseudoephedrine
 phenylephrine

Anti-leukotrienes

montelukast (*Singulair*[®])
 zafirlukast (*Accolate*[®])
 zileuton (*Zyflo*[®])

April

Number 4 - New Drugs 2006-2007

Reviews the new molecular entities you are most likely to encounter in practice, with the indication, usual doses, and major drug interactions for each. Also includes a brief overview of an additional 12 new drugs.

Drugs reviewed in this issue:

arformoterol (*Brovana*TM)
 herpes zoster vaccine (*Zostavax*[®])
 HPV vaccine (*Gardasil*[®])

paliperidone (*Invega*TM)
 posaconazole (*Noxafil*[®])
 rasagiline (*Azilect*[®])

sitagliptin (*Januvia*TM)
 varenicline (*Chantix*[®])

Drugs briefly described:

ciclesonide (*Omnaris*TM)
 darunavir (*Prezista*TM)
 dasatinib (*Sprycel*[®])
 ecamsule sunscreen (*Anthelios SX*)

estradiol gel 0.06% (*Elestrin*TM)
 immune globulin (*Vivaglobin*[®])
 nabilone (*Cesamet*TM)
 pamitumumab (*Vectibix*TM)

ranibizumab (*Lucentis*TM)
 rotavirus vaccine (*Rota Teq*[®])
 telbivudine (*Tyzeka*TM)
 vorinostat (*Zolinza*TM)

May

Number 5 - Fluoroquinolone Update

Reviews developments in clinical use of this antibiotic class including resistance issues, shorter versus standard durations of therapy, and pediatric use of fluoroquinolones. Discusses new safety concerns that came to light after their widespread use. Provides practical information for identifying factors that may increase a patient's risk of adverse effects from fluoroquinolones.

Drugs included in this issue:

ciprofloxacin (*Cipro*[®], others)
 ciprofloxacin, extended-release (*Cipro*[®] XR)

gatifloxacin -withdrawn
 gemifloxacin (*Factive*[®])

levofloxacin (*Levaquin*[®])
 moxifloxacin (*Avelox*[®])

<p>June</p> <p>Number 6 - Eating Disorders: An Update on Recognition, Diagnosis and Treatment</p> <p>Reviews characteristics and medical complications of anorexia nervosa, bulimia nervosa, and binge eating disorder. Discusses common dietary supplements marketed for weight loss, and OTC products abused by individuals with eating disorders. Provides a detailed overview of drug treatments with evidence for effectiveness in eating disorders.</p> <p>Drugs included in this issue:</p> <p><u>OTC Laxatives</u> <i>Lubricant</i> (mineral oil) <i>Saline</i> (magnesium citrate, magnesium hydroxide, magnesium sulfate) <i>Stimulant</i> (senna, bisacodyl, castor oil, cascara sagrada)</p>	<p><u>Dietary Supplements Marketed for Weight Loss</u> bitter orange chitosan chromium picolinate green tea guar gum</p>	<p><u>Drugs Used for Eating Disorders</u> <i>atypical antipsychotics</i> (aripiprazole, olanzapine, quetiapine, risperidone) SSRIs (fluoxetine, sertraline) sibutramine (<i>Meridia</i>[®]) topiramate (<i>Topamax</i>[®])</p>
<p>July</p>	<p>Number 7 - Type 2 Diabetes: An Update on Drug Therapy</p> <p>Describes the changes in drug therapy recommended in the new treatment algorithm developed by major American and European diabetes organizations. Six new medications are detailed, with an emphasis on where each fits in the overall management of type 2 diabetes. A brief review of the established oral drugs (metformin, sulfonylureas, thiazolidinediones, meglitinides, and alpha-glucosidase inhibitors) is also included.</p> <p>Drugs reviewed in this issue:</p>	<p><u>Insulin Sensitizers</u> metformin (<i>Glucophage</i>[®]) Thiazolidinediones [pioglitazone (<i>Actos</i>[®]), rosiglitazone (<i>Avandia</i>[®])] <u>Alpha Glucosidase Inhibitors</u> acarbose (<i>Precose</i>[®]), miglitol (<i>Glyset</i>[®])</p>
<p>August</p>	<p><u>Insulin Secretagogues</u> Sulfonylureas (glipizide, glyburide, glimepiride) Meglitinides [nateglinide (<i>Starlix</i>[®]) repaglinide (<i>Prandin</i>[®])] <u>Incretin Mimetics and Enhancers</u> exenatide (<i>Byetta</i>[®]), pramlintide (<i>Symlin</i>[®]), sitagliptin (<i>Januvia</i>[™])</p>	<p><u>Insulins</u> <i>rapid-acting insulins</i> (regular, lispro, aspart, glulisine, insulin powder for inhalation) <i>intermediate-acting</i> (NPH) <i>long-acting</i> (glargine, detemir)</p>
<p>September</p>	<p>No issue</p>	
<p>September</p>	<p>Number 8 - Smoking Cessation for the Busy Clinician</p> <p>Emphasizes the Ask, Advise, Refer method for promoting tobacco cessation. Provides comparative information for all FDA approved products for smoking cessation including adverse effects, dosing, advantages and patient counseling.</p> <p>Drugs reviewed in this issue:</p>	<p>nicotine gum (<i>Nicorette</i>[®], <i>generic</i>) nicotine lozenge (<i>Commit</i>[™], <i>generic</i>) nicotine oral inhaler (<i>Nicotrol</i>[®] <i>Inhaler</i>)<i>erm</i>[®]</p>
<p>October</p>	<p>Number 9 - NSAIDs and Peptic Ulcer Disease: Update on Risk, Risk Reduction, and Treatment</p> <p>Reviews NSAID-related peptic ulcer disease and upper gastrointestinal complications. Provides an update on the current strategies used to reduce the risk of these events. Discusses gastroprotective strategies with a focus on the role of cotherapy with proton pump inhibitors and the use of COX-2 inhibitors in patients who require chronic NSAIDs.</p> <p>Drugs included in this issue:</p>	<p>nicotine nasal spray (<i>Nicotrol NS</i>[®]) nicotine transdermal patch (<i>Nicotrol</i>[®] <i>Inhaler</i>)<i>erm</i>[®] bupropion SR (<i>Zyban</i>[®], <i>generic</i>) varenicline (<i>Chantix</i>[®])</p>
<p>November</p>	<p><u>NSAIDs</u> <i>Nonselective</i> (aspirin, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, naproxen, piroxicam, sulindac, tolmetin) <i>Partially COX-2 Selective</i> (celecoxib, diclofenac, etodolac, meloxicam, nabumatone) <i>highly COX-2 Selective</i> (lumiracoxib, rofecoxib, valdecoxib)</p>	<p><u>Proton Pump Inhibitors</u> omeprazole (<i>Prilosec</i>[®], <i>Prilosec OTC</i>[®], <i>others</i>) lansoprazole (<i>Prevacid</i>[®]) rabeprazole (<i>Aciphex</i>[®]) pantoprazole (<i>Protonix</i>[®]) esomeprazole (<i>Nexium</i>[™])</p>
<p>November</p>	<p>Number 10 - Legal Issues: Recent Federal, Regulatory and Legal Developments Affecting Pharmacy & Medical Practice</p> <p>Provides brief discussions regarding regulatory and legal developments that occurred at the federal level with direct importance to pharmacy and medical practice, as well as to public health and safety. Agencies involved include the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA) and the Center for Medicare and Medicaid Services (CMS). The implications of each development are highlighted in an inset accompanying each section.</p>	<p><u>H2-Receptor Antagonists</u> cimetidine (<i>Tagamet</i>[®], <i>Tagamet HB</i>[®] 200, <i>others</i>) famotidine (<i>Pepcid</i>[®], <i>Pepcid AC</i>[®], <i>others</i>) nizatidine (<i>Axid</i>[®], <i>Axid AR</i>[®]) ranitidine (<i>Zantac</i>[®], <i>Zantac 75</i>[®], <i>others</i>)</p>
<p>December</p>	<p>Number 11 - Dietary Supplements: In the Treatment of Cardiovascular Disease</p> <p>Summarizes the evidence and makes recommendations concerning the use of dietary supplements for the treatment of common cardiovascular diseases. The most frequently reported adverse effects for each supplement are listed. Moderate and major interactions that are supported by at least some clinical evidence or that are potentially severe are presented in a detailed table.</p> <p>Supplements reviewed in this issue:</p>	<p><u>Prostaglandin</u> misoprostol (<i>Cytote</i>[®]) <u>Mucosal Protective</u> sucralfate (<i>Carafate</i>[®], <i>others</i>)</p>
	<p><u>Supplements Used for Lipid Disorders</u> coenzyme Q10, garlic, omega-3 fatty acids, red yeast rice, policosanol, soy, tea</p>	<p><u>Supplements Used for Chronic Heart Failure</u> coenzyme Q10, hawthorn <u>Supplements Used for Hypertension</u> coenzyme Q10, garlic</p>
		<p><u>Supplements Used for Peripheral Vascular Disease</u> horse chestnut seed extract, Ginkgo biloba extract</p>